Skip to main content
Explore URMC

menu

Multiple Myeloma: A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

Research Question:
How safe is and what is the tolerability of denosumab in newly diagnosed or relapsed multiple myeloma patients?

Basic Study Information

Purpose:
If you decide to participate in this study you will receive denosumab every 4 weeks for a total of 12 cycles.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02833610?term=15-571&rank=1
Study Reference #: UMMY17073

Lead Researcher (Principal Investigator)

Lead Researcher: Brea Lipe

Study Contact Information

Study Coordinator: Andrew Bui
Phone: (585) 276-4405
Email: Andrew_Bui@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Multiple Myeloma

Return to Search